CURNZ Stock Overview
Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Curatis Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 14.05 |
| 52 Week High | CHF 17.80 |
| 52 Week Low | CHF 5.10 |
| Beta | 0 |
| 1 Month Change | 10.63% |
| 3 Month Change | 56.46% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -5.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| CURNZ | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 6.4% | 1.0% | 3.3% |
| 1Y | n/a | -1.1% | 10.6% |
Return vs Industry: Insufficient data to determine how CURNZ performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CURNZ performed against the UK Market.
Price Volatility
| CURNZ volatility | |
|---|---|
| CURNZ Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine CURNZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Roland Rutschmann | curatis.com |
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson’s disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, gastroenterologic, immunomodulator, thyreostatic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington’s disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema in pediatric patients; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and KIN001 that is in Phase I clinical trial for the treatment of rare inflammatory and fibrotic diseases.
Curatis Holding AG Fundamentals Summary
| CURNZ fundamental statistics | |
|---|---|
| Market cap | CHF 69.28m |
| Earnings (TTM) | CHF 0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs CURNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CURNZ income statement (TTM) | |
|---|---|
| Revenue | CHF 0 |
| Cost of Revenue | CHF 0 |
| Gross Profit | CHF 0 |
| Other Expenses | CHF 0 |
| Earnings | CHF 0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CURNZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 13:21 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Curatis Holding AG is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bob Pooler | ValuationLAB AG |